Gene therapy for neurodegenerative and ocular diseases using lentiviral vectors

被引:26
|
作者
Ralph, GS [1 ]
Binley, K [1 ]
Wong, LF [1 ]
Azzouz, M [1 ]
Mazarakis, ND [1 ]
机构
[1] Oxford Biomed Plc, Medawar Ctr, Oxford OX4 4GA, England
关键词
gene transfer; interfering RNA (RNAi); lentivirus; neurodegeneration; ocular disease; retinal disorder; viral vector;
D O I
10.1042/CS20050158
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Gene therapy holds great promise for the treatment of a wide range of inherited and acquired disorders. The development of viral vector systems to mediate safe and long-lasting expression of therapeutic transgenes in specific target cell populations is continually advancing. Gene therapy for the nervous system is particularly challenging due to the post-mitotic nature of neuronal cells and the restricted accessibility of the brain itself. Viral vectors based on lentiviruses provide particularly attractive vehicles for delivery of therapeutic genes to treat neurological and ocular diseases, since they efficiently transduce non-dividing cells and mediate sustained transgene expression. Furthermore, novel routes of vector delivery to the nervous system have recently been elucidated and these have increased further the scope of lentiviruses for gene therapy application. Several studies have demonstrated convincing therapeutic efficacy of lentiviral-based gene therapies in animal models of severe neurological disorders and the push for progressing such vectors to the clinic is ongoing. This review describes the key features of lentiviral vectors that make them such useful tools for gene therapy to the nervous system and outlines the major breakthroughs in the potential use of such vectors for treating neurodegenerative and ocular diseases.
引用
收藏
页码:37 / 46
页数:10
相关论文
共 50 条
  • [41] Development of gene therapy for hematopoietic stem cells using lentiviral vectors
    Woods, NB
    Ooka, A
    Karlsson, S
    LEUKEMIA, 2002, 16 (04) : 563 - 569
  • [42] Gene therapy of Fanconi anemia: preclinical efficacy using lentiviral vectors
    Galimi, F
    Noll, M
    Kanazawa, Y
    Lax, T
    Chen, C
    Grompe, M
    Verma, IM
    BLOOD, 2002, 100 (08) : 2732 - 2736
  • [43] Novel Dual-Insulated Lentiviral Vectors for Gene Therapy of Sickle Cell Diseases
    Romero, Z.
    Wherley, J.
    Cooper, A. R.
    Urbinati, F.
    Campo, B.
    Kaufman, M. L.
    Hollis, R. P.
    Senadheera, S.
    Kohn, D. B.
    HUMAN GENE THERAPY, 2013, 24 (12) : A77 - A77
  • [44] Gene therapy for neurodegenerative diseases
    Muramatsu, S. I.
    HUMAN GENE THERAPY, 2016, 27 (11) : A10 - A11
  • [45] Gene Therapy for Neurodegenerative Diseases
    Sudhakar, Vivek
    Richardson, R. Mark
    NEUROTHERAPEUTICS, 2019, 16 (01) : 166 - 175
  • [46] Gene Therapy for Neurodegenerative Diseases
    Vivek Sudhakar
    R. Mark Richardson
    Neurotherapeutics, 2019, 16 : 166 - 175
  • [47] Gene therapy for neurodegenerative diseases
    O'Connor, Deirdre M.
    Boulis, Nicholas M.
    TRENDS IN MOLECULAR MEDICINE, 2015, 21 (08) : 504 - 512
  • [48] Design, Validation, and Translation of AAV Gene Therapy Vectors for the Treatment of Ocular Diseases
    Hirsch, Matthew
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [49] Viral vectors for neurotrophic factor delivery: A gene therapy approach for neurodegenerative diseases of the CNS
    Lim, Seung T.
    Airavaara, Mikko
    Harvey, Brandon K.
    PHARMACOLOGICAL RESEARCH, 2010, 61 (01) : 14 - 26
  • [50] Opportunities for the use of lentiviral vectors in human gene therapy
    Galimi, F
    Verma, IM
    LENTIVIRAL VECTORS, 2002, 261 : 245 - 254